The second dose group clinical trial of IMM01 project was successfully completed

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherapy products. The product line main...

2020-03-26

2020 Annual Conference

The annual celebration of the 2019 Annual Conference ended smoothly. Thank all colleagues of the company for their hard work and dedication in the past year! Work Work Hard，Day Day Up! Happy New Year to you! ...

2020-01-19

ImmuneOnco was awarded Star Light List-2019 China's Top 50 Biopharmaceutical Enterprises with the Most Innovative Ability

On August 4, 2019, ImmuneOnco won the award of Star Light List - the top 50 innovative enterprises of China's biomedical enterprises in 2019. The selection was made by enterprises in the field of bio-innovative drugs from the front line of the country, incl......

2019-08-06

Conference on Phase I Clinical Trial Scheme of ImmuneOnco IMM0306 Project solemnly held

...

2019-08-05

Initiation Meeting of Phase I Clinical Trials of ImmuneOnco IMM01

Dr. Tian Wenzhi, founder of ImmuneOnco, and Director Qiu Lugui, Hospital of Hematology, Chinese Academy of Medical Sciences made opening remarks. Subsequently, the research team conducted in-depth and detailed discussions on the design of the re......

2019-08-02